Moreover applying PARP inhibitors to delay secondary necrosis might control the tumor lysis syndrome, where the intracellular content spilling out from the abruptly dying large number of cells poisoning the whole body. This evidence concerns the gene PARP1 and Tumor Lysis Syndrome.